Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Maisonneuve-Rosemont Hospital19 enrolled

Overview

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Observation of primary outcome: * Overall Survival * Disease-free survival Influencing factors that will be observe: * Sex * Blood loss * Time of surgery * Number of resection and anastomosis * Peritoneal Index (PI score) * Cytoreductibility (CCR score)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Peritoneal Mesotheliomas

Interventions

Cytoreductive surgery and HIPECPROCEDURE

Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Peritoneal mesothelioma Exclusion Criteria: * Non resectable disease

Locations (1)

Maisonneuve Rosemont Hospital

Montreal, Quebec, Canada

Outcomes

Primary Outcomes

Overall survival

Time frame: 5 years

Secondary Outcomes

Disease-Free survival

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.